Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Depreciation & Amortization (CF) (2016 - 2024)

Spero Therapeutics (SPRO) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $2000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Depreciation & Amortization (CF) fell 98.15% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Mar 2025, down 99.21%, and an annual FY2024 reading of $2000.0, down 99.46% over the prior year.
  • Depreciation & Amortization (CF) was $2000.0 for Q2 2024 at Spero Therapeutics, down from $38000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $294000.0 in Q2 2022 and bottomed at $2000.0 in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $155588.2, with a median of $159000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) soared 413.11% in 2020, then tumbled 98.15% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $191000.0 in 2020, then changed by 0.0% to $191000.0 in 2021, then plummeted by 32.46% to $129000.0 in 2022, then tumbled by 70.54% to $38000.0 in 2023, then plummeted by 94.74% to $2000.0 in 2024.
  • Business Quant data shows Depreciation & Amortization (CF) for SPRO at $2000.0 in Q2 2024, $38000.0 in Q4 2023, and $108000.0 in Q3 2023.